| Summary: | 碩士 === 國立臺灣大學 === 護理學研究所 === 96 === Chemotherapy-Induced Peripheral Neuropathy (CIPN) is one of the major side effects from selected chemotherapeutic agents, including platinum, taxanes, vinca alkaloids. Limited studies have explored these problems. The purpose of this study is to examine (1) the patients’ experiences related to CIPN and peripheral neuropathic pain (PNP) and (2) the relationships of CIPN (and PNP) and anxiety, depression, and quality of sleep in lung cancer patients receiving the above mentioned drugs. A cross-sectional study with purposive sampling was used. Data were collected by (1) Brief Peripheral Neuropathy Inventory (BPNI), (2) Neuropathic Pain Scale (NPS), Symptom Severity Scale (SSS), Hospital Anxiety and Depression Scale (HADS), Medical Outcome Study Sleep Scale (MOS-sleep). Data were collected at a medical center in Taipei. A total of 65 lung cancer patients were recruited. The results showed that 83% had CIPN symptoms with blurred vision (55.4%), numbness on hands ( 43.1 %), numbness on feet (40 %) ranked as the top three symptoms. There are 28% of patients had PNP with “unpleasant,”“intense,”“deep pain” and“surface pain,” described by patients. There were significant correlation among BPNI and NPS, the numbers of chemotherapy courses, and depression. The result suggested the potential problems from CIPN and PNP in lung cancer patients with chemotherapy. Longitudinal studies would be necessary to further examine the changes of CIPN and PNS across time in lung cancer patients. These results can help health professionals better understanding patients’ problems related to CIPN and might enhance patients’quality of life.
|
|---|
